Skip to content

Study · Systematic review · n = 6,515 · 2026

3 results

Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.

Mansouri ES, Queiroga F, Barbosa LM, Azevedo AK, Donaldy W, Mirbolouk MJ, Blair CV, Rivera A, Ferreira Felix I, Abreu M, Deshmukh AJ, DeSimone CV

Journal of the American Heart Association9 Sept 2026Cited by 1 (Europe PMC)

PMID42714458 (opens in a new tab)DOI10.1161/jaha.125.044249 (opens in a new tab)PepBankPUB-42714458
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In adults with overweight or obesity, tirzepatide was not significantly associated with atrial fibrillation versus placebo (pooled OR 2.20, 95% CrI 0.81-6.75).

    In plain wordsIn adults with overweight or obesity, tirzepatide was not clearly linked to more atrial fibrillation than placebo.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAtrial fibrillation incidence
    Study

    n = 6,515

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Pooled OR
    2.2 ratio
    atrial fibrillation

    Source sentences

    Summary
    The pooled OR was 2.20 (95% CrI, 0.81-6.75) for atrial fibrillation
    2 context sentences
    Summary · context
    PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing tirzepatide versus placebo for individuals with overweight or obesity.
    Summary · context
    Our meta-analysis included 10 randomized controlled trials, including 6515 individuals, of whom 4491 (68.9%) were randomized to tirzepatide.
  2. 02HumanSystematic reviewSafety outcome

    In adults with overweight or obesity, tirzepatide was not significantly associated with atrial arrhythmia versus placebo (pooled OR 2.16, 95% CrI 0.90-5.87).

    In plain wordsIn adults with overweight or obesity, tirzepatide was not clearly linked to more atrial arrhythmia than placebo.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAtrial arrhythmia incidence
    Study

    n = 6,515

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Pooled OR
    2.16 ratio
    atrial arrhythmia

    Source sentences

    Summary
    2.16 (95% CrI, 0.90-5.87) for atrial arrhythmia
    2 context sentences
    Summary · context
    PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing tirzepatide versus placebo for individuals with overweight or obesity.
    Summary · context
    Our meta-analysis included 10 randomized controlled trials, including 6515 individuals, of whom 4491 (68.9%) were randomized to tirzepatide.
  3. 03HumanSystematic reviewSafety outcome

    In adults with overweight or obesity, tirzepatide was associated with higher odds of any arrhythmia versus placebo (pooled OR 1.84, 95% CrI 1.04-3.90).

    In plain wordsIn adults with overweight or obesity, tirzepatide was linked to higher odds of any heart rhythm problem than placebo, though event rates were low.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAny arrhythmia incidence
    Study

    n = 6,515

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Pooled OR
    1.84 ratio
    any arrhythmia

    Source sentences

    Summary
    1.84 (95% CrI, 1.04-3.90) for any arrhythmia.
    3 context sentences
    Summary · context
    Although higher odds of overall arrhythmias were observed, event rates were low and the findings should be interpreted cautiously.
    Summary · context
    PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing tirzepatide versus placebo for individuals with overweight or obesity.
    Summary · context
    Our meta-analysis included 10 randomized controlled trials, including 6515 individuals, of whom 4491 (68.9%) were randomized to tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.